Sequenom Inc (SQNM): Daniel S Md Grosu , SVP & CMO of Sequenom Inc purchased 30,000 shares on May 11, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.11 per share for a total value of $33,300.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 6, 2016, Carolyn Beaver (CFO) purchased 30,000 shares at $1.13 per share price.On May 6, 2016, Jeffrey D Linton (Sr VP, GC & Secretary) purchased 10,000 shares at $1.15 per share price.Also, On May 6, 2016, Den Boom Dirk Van (CEO) purchased 30,000 shares at $1.13 per share price.On Jan 4, 2016, Capital Management Llc Camber (10% owner) purchased 665,435 shares at $1.61 per share price.
Shares of Sequenom (SQNM) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.03 points or -2.63% at $1.11 with 7,36,022 shares getting traded. Post opening the session at $1.17, the shares hit an intraday low of $1.09 and an intraday high of $1.17 and the price vacillated in this range throughout the day. The company has a market cap of $132 M and the number of outstanding shares has been calculated to be 11,92,16,003 shares. The 52-week high of Sequenom is $3.87 and the 52-week low is $1.08.
Company has been under the radar of several Street Analysts.Sequenom is Upgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Sell on the company shares. The Rating was issued on Mar 3, 2016.
Sequenom Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company’s diagnostic services are provided through its wholly owned subsidiary Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in and by Sequenom Laboratories as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of and reimbursement for its prenatal LDTs and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories’ test offerings in the prenatal market include MaterniT21 PLUS LDT HerediT CF LDT SensiGene RhD LDT VisibiliT LDT and Test Send-out Agreements.